@prefix : <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness> .

<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness> rdf:type owl:Ontology ;
                                                                   owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                   rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255520/"^^xsd:anyURI ;
                                                                   rdfs:label "Fluoxetine and Deafness"^^xsd:Literal ;
                                                                   owl:versionInfo "draft-v0.95-20210611"@en .

#################################################################
#    Annotation properties
#################################################################

###  http://purl.org/dc/elements/1.1/publisher
dc:publisher rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/terms/hasVersion
terms:hasVersion rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#exactMatch
skos:exactMatch rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#inScheme
skos:inScheme rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#notation
skos:notation rdf:type owl:AnnotationProperty .


#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


###  http://purl.org/mp/supportedByData
mp:supportedByData rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#ConclusionContent
:ConclusionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Conclusion ;
                   OpenPVSignal:has_content "Despite the clear involvement of the serotonin transmission in the hearing processing and the physiopathology of depression, there is no evidence in the literature that antidepressants would cause deafness, tinnitus or hyperacusis, and the use of antidepressants for the treatment of tinnitus has been widely studied but with inconclusive evidence. However, the substantial number of case reports documenting a positive de- and rechallenge support a possible causal relationship between the administration of fluoxetine and the investigated hearing disorders." ;
                   rdfs:label "Conclusion content" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Depression_associated_with_hearing_impairment
:Depression_associated_with_hearing_impairment rdf:type owl:NamedIndividual ,
                                                        obo:OAE_0001182 ,
                                                        OpenPVSignal:Warning_Information ;
                                               OpenPVSignal:has_potential_confounding_factor :depressiveIllness ;
                                               OpenPVSignal:refers_to_adverse_effect <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Hearing_impairment_(SMQ)> ;
                                               mp:references :Ref.6 ;
                                               OpenPVSignal:has_content "In fact, the underlying disease, depression, has been associated with several types of hearing impairments, which might be related both to the basic molecular mechanism and to the adaptive processes of the patient.6" ;
                                               rdfs:label "Depression associated with hearing impairment" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#DiscussionContent
:DiscussionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Discussion ;
                   mp:references :Ref.10 ,
                                 :Ref.11 ,
                                 :Ref.12 ,
                                 :Ref.4 ,
                                 :Ref.5 ,
                                 :Ref.7 ,
                                 :Ref.8 ,
                                 :Ref.9 ;
                   OpenPVSignal:has_content """Serotonin is an important neurotransmitter in the auditory system, with both excitatory and inhibitory actions in different levels of the processing of sensory information of the acoustic signal. It has been hypothesized that the primary functions of the 5-HT system in the brain are to facilitate motor output and concurrently inhibit sensory information processing.4 The location of serotonin receptors in the cochlear nucleus and the inferior colliculus of the brainstem is well established, and it is postulated that serotonin may have a modulatory effect in the processing of the acoustic signal producing a tonic inhibition of the acoustic pathways.5 evoked emissions, higher SCAN-A (auditory processing test) composite scores, and smaller amplitude growth functions for auditory brainstem response peak V and auditory late response peak N(1)P(2) while on SSRI medication.11,12 Nevertheless, there is not a direct clinical correlation between the changes in those parameters and the clinical level of hearing, and the results must be taken with caution.
Nevertheless, a correlation between the level of serotonin neurotransmitter in the auditory system and the hearing capacities has not been established, nor the changes in auditory processing related to drugs that might modify those levels. In fact, the underlying disease, depression, has been associated with several types of hearing impairments, which might be related both to the basic molecular mechanism and to the adaptive processes of the patient.6
Tinnitus, for example, has been described either as a symptom of depression that abates when the patient improves, or as a problem that is susceptible to be treated with antidepressants.
Several research projects have studied the possible association between depression, tinnitus and the therapeutic use of SSRIs on the treatment of tinnitus in both depressed and not depressed patients, including a double-blind clinical trial.7 Currently there is insufficient evidence to say that antidepressant drug therapy improves tinnitus and if so, it might be confined to patients having tinnitus associated with both depression and anxiety.6,8,9,10
The cases of deafness and hyperacusis are difficult to evaluate. There are a number of reports of deafness associated with fluoxetine (122), and for some (20) the data indicates that the audition recovered when the drugs were stopped, but almost all cases lack information on an objective measurement of the audition (audiometry).
Some researchers tried to associate changes in several objective determinations of the hearing system (from otoscopy to the measurement of the central component of audition as brainstem responses) to the use of antidepressants in both depressed patients and non-depressed controls.
Results showed significantly smaller transient evoked emissions, higher SCAN-A (auditory processing test) composite scores, and smaller amplitude growth functions for auditory brainstem response peak V and auditory late response peak N(1)P(2) while on SSRI medication.11,12 Nevertheless, there is not a direct clinical correlation between the changes in those parameters and the clinical level of hearing, and the results must be taken with caution.""" ;
                   rdfs:label "Discussion content" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Double-blind_clinical_trial
:Double-blind_clinical_trial rdf:type owl:NamedIndividual ,
                                      obo:OAE_0001125 ,
                                      OpenPVSignal:Clinical_trial_information ;
                             OpenPVSignal:has_potential_confounding_factor :depressiveIllness ;
                             OpenPVSignal:refers_to_adverse_effect :tinnitus ;
                             OpenPVSignal:refers_to_class :Selective_serotonin_reuptake_inhibitors ;
                             mp:references :Ref.7 ;
                             OpenPVSignal:has_content "Tinnitus, for example, has been described either as a symptom of depression that abates when the patient improves, or as a problem that is susceptible to be treated with antidepressants. Several research projects have studied the possible association between depression, tinnitus and the therapeutic use of SSRIs on the treatment of tinnitus in both depressed and not depressed patients, including a double-blind clinical trial.7" ;
                             rdfs:label "Double-blind clinical trial" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Dr_Carlos_de_las_Cuevas
:Dr_Carlos_de_las_Cuevas rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Author ;
                         OpenPVSignal:has_first_name "Carlos" ;
                         OpenPVSignal:has_last_name "de Las Cuevas" ;
                         rdfs:label "Dr Carlos de Las Cuevas" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Dr_Emilio_J_Sanz
:Dr_Emilio_J_Sanz rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Author ;
                  OpenPVSignal:has_first_name "Emilio" ;
                  OpenPVSignal:has_last_name "Sanz" ;
                  rdfs:label "Dr Emilio J. Sanz" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Fluoxetine_and_Deafness
:Fluoxetine_and_Deafness rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Pharmacovigilance_Signal_Report ;
                         OpenPVSignal:refers_to_author :Dr_Carlos_de_las_Cuevas ,
                                                       :Dr_Emilio_J_Sanz ;
                         OpenPVSignal:refers_to_signal :pvSignal ;
                         OpenPVSignal:has_creation_date "01/08/2020" ;
                         OpenPVSignal:has_overall_conclusion "causal association probable" ;
                         rdfs:label "Fluoxetine and Deafness" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#IC025ForDeafnessAndFluoxetine
:IC025ForDeafnessAndFluoxetine rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                               OpenPVSignal:refers_to_adverse_effect :deafness ;
                               OpenPVSignal:refers_to_drug :fluoxetine ;
                               OpenPVSignal:refers_to_information_component :ICForDeafnessAndFluoxetine ;
                               OpenPVSignal:has_value -0.07 ;
                               OpenPVSignal:refers_to_number_of_reports 122 ;
                               rdfs:label "IC025 for deafness and fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#IC025ForHyperacusisAndFluoxetine
:IC025ForHyperacusisAndFluoxetine rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                  OpenPVSignal:refers_to_adverse_effect :hyperacusis ;
                                  OpenPVSignal:refers_to_drug :fluoxetine ;
                                  OpenPVSignal:refers_to_information_component :ICForHyperacusisAndFluoxetine ;
                                  OpenPVSignal:has_value 0.40 ;
                                  OpenPVSignal:refers_to_number_of_reports 24 ;
                                  rdfs:label "IC025 for hyperacusis and fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#IC025ForTinnitusAndFluoxetine
:IC025ForTinnitusAndFluoxetine rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                               OpenPVSignal:refers_to_adverse_effect :tinnitus ;
                               OpenPVSignal:refers_to_drug :fluoxetine ;
                               OpenPVSignal:refers_to_information_component :ICForTinnitusAndFluoxetine ;
                               OpenPVSignal:has_value 0.59 ;
                               OpenPVSignal:refers_to_number_of_reports 324 ;
                               rdfs:label "IC025 for tinnitus and fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#ICForDeafnessAndFluoxetine
:ICForDeafnessAndFluoxetine rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                            OpenPVSignal:refers_to_adverse_effect :deafness ;
                            OpenPVSignal:refers_to_drug :fluoxetine ;
                            OpenPVSignal:has_value 0.20 ;
                            OpenPVSignal:refers_to_number_of_reports 122 ;
                            rdfs:label "IC for deafness and fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#ICForHyperacusisAndFluoxetine
:ICForHyperacusisAndFluoxetine rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                               OpenPVSignal:refers_to_adverse_effect :hyperacusis ;
                               OpenPVSignal:refers_to_drug :fluoxetine ;
                               OpenPVSignal:has_value 1.04 ;
                               OpenPVSignal:refers_to_number_of_reports 24 ;
                               rdfs:label "IC for hyperacusis and fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#ICForTinnitusAndFluoxetine
:ICForTinnitusAndFluoxetine rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                            OpenPVSignal:refers_to_adverse_effect :tinnitus ;
                            OpenPVSignal:refers_to_drug :fluoxetine ;
                            OpenPVSignal:has_value 0.75 ;
                            OpenPVSignal:refers_to_number_of_reports 324 ;
                            rdfs:label "IC for tinnitus and fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Insufficient_evidence
:Insufficient_evidence rdf:type owl:NamedIndividual ,
                                obo:OAE_0001125 ;
                       OpenPVSignal:has_potential_confounding_factor :anxiety ,
                                                                     :depressiveIllness ;
                       OpenPVSignal:refers_to_adverse_effect :tinnitus ;
                       OpenPVSignal:refers_to_class :Selective_serotonin_reuptake_inhibitors ;
                       mp:references :Ref.10 ,
                                     :Ref.6 ,
                                     :Ref.8 ,
                                     :Ref.9 ;
                       OpenPVSignal:has_content "Currently there is insufficient evidence to say that antidepressant drug therapy improves tinnitus and if so, it might be confined to patients having tinnitus associated with both depression and anxiety.6,8,9,10" ;
                       rdfs:label "Insufficient evidence" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#IntroductionContent
:IntroductionContent rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Introduction ;
                     mp:references :Ref.2 ,
                                   :Ref.3 ;
                     OpenPVSignal:has_content "The drug-ADR combination of fluoxetine and deafness was highlighted during testing of a new quantitative method for detecting potential signals at the UMC in 2012.2 Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) used for major depressive illness, obsessive-compulsive disorder and bulimia nervosa.3 Besides deafness, the hearing disorders tinnitus and hyperacusis (an increased sensitivity to sound) were also considered." ;
                     rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#LiteratureAndLabelling
:LiteratureAndLabelling rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Literature_information ;
                        mp:references :Ref.1 ,
                                      :Ref.3 ;
                        OpenPVSignal:has_content "The US PI lists tinnitus as a frequent adverse event and deafness and hyperacusis as rare adverse events.1 The UK Summary of Product Characteristics (SPC) lists tinnitus although frequency is not known.3" ;
                        rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#MechanismOfFluoxetine
:MechanismOfFluoxetine rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Mechanism ;
                       mp:references :Ref.3 ;
                       OpenPVSignal:has_content "Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) used for major depressive illness, obsessive-compulsive disorder and bulimia nervosa.3" ;
                       rdfs:label "Mechanism of Fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#MechanismOfOtotoxicityBySSRI
:MechanismOfOtotoxicityBySSRI rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Adverse_Effect_Mechanism ;
                              OpenPVSignal:refers_to_adverse_effect <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Hearing_impairment_(SMQ)> ;
                              mp:references :Ref.4 ,
                                            :Ref.5 ;
                              OpenPVSignal:has_content "Serotonin is an important neurotransmitter in the auditory system, with both excitatory and inhibitory actions in different levels of the processing of sensory information of the acoustic signal. It has been hypothesized that the primary functions of the 5-HT system in the brain are to facilitate motor output and concurrently inhibit sensory information processing.4 The location of serotonin receptors in the cochlear nucleus and the inferior colliculus of the brainstem is well established, and it is postulated that serotonin may have a modulatory effect in the processing of the acoustic signal producing a tonic inhibition of the acoustic pathways.5" ;
                              rdfs:label "Mechanism of ototoxicity by SSRI" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "US PI for fluoxetine (Prozac). URL: http://www accessdata.fda.gov/scnpts/cder/drugsatfda. Accessed: 16 January 2013." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Oishi N, Kanzaki S, Shinden S, Saito H, Inoue Y, Ogawa K. Effects of selective serotonin reuptake inhibitor on treating tinnitus in patients stratified for presence of depression or anxiety. Audiol Neurootol. 2010;15(3):187-93." ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Gopal KV, Briley KA, Goodale ES, Hendea OM. Selective serotonin reuptake inhibitors treatment effects on auditory measures in depressed female subjects. Eur J Pharmacol. 2005 Sep 27;520(1- 3):59-69." ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Goodale ES. The effects of selective serotonin reuptake inhibitors (SSRI) on auditory measures in clinically depressed subjects. Master Thesis, University of North Texas; May 2002." ;
        rdfs:label "Ref.12" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Caster O, Norén GN, Madigan D, Bate A. Large-scale regression-based pattern discovery: the example of screening the WHO global drug safety database. Statistical analysis and data mining 2010;3(4):197-208." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "UK SPC for fluoxetine (Prozac). URL: http://www medicines.org.uk. Accessed: 16 January 2013." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Jacobs BL, Fornal CA. 5-HT and motor control: a hypothesis. Trends Neurosci. 1993 Sep;16(9):346-52." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Thompson GC, Thompson AM, Garrett KM, Britton BH. Serotonin and serotonin receptors in the central auditory system. Otolaryngol Head Neck Surg. 1994 Jan;110(1):93-102." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Baldo P, Doree C, Lazzarini R, Molin P, McFerran DJ. Antidepressants for patients with tinnitus. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003853." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Zöger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering - a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006 Feb;26(1):32-9." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Robinson SK, Viirre ES, Bailey KA, Gerke MA, Harris JP, Stein MB. Randomized placebo- controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med. 2005 Nov- Dec;67(6):981-8." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Dib GC, Kasse CA, Alves de Andrade T, Gurgel Testa JR, Cruz OL. Tinnitus treatment with trazodone. Braz J Otorhinolaryngol. 2007 May- June;73(3):390-7." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#ReportsInVgibase
:ReportsInVgibase rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Free_text_reporting_element ;
                  OpenPVSignal:has_content """The WHO Global ICSR database, VigiBase™, contains 122 reports, from the 1980s to 2 December 2012, in which deafness is associated with the use of fluoxetine. There are also 324 reports of tinnitus and 24 reports of hyperacusis related to the same drug. Most of the reports of deafness are from the US and the rest are from Canada, UK, Netherlands and France. The distribution of reports for tinnitus and hyperacusis is also multinational although most are from the US. Approximately 20% of these reports contain enough information to calculate a time to onset and in a third of these the time to onset is the same day as the beginning of the treatment. There are also reports with delays of several days or months and a few reports with time to onset over one year.
Most of the case reports lack sufficient information (such as dates for use of the medication and onset of the reaction, medical history and other data that could be included in free text fields) to make a reliable assessment. For deafness with fluoxetine there are three positive rechallenges and 20 positive dechallenges and the IC value (IC025) is
0.20 (-0.07). In the case of tinnitus with fluoxetine there are seven positive rechallenges and 54 positive dechallenges and the IC is 0.75 (0.59). The 24 cases of hyperacusis with fluoxetine include one positive rechallenge and six positive dechallenges,
and the IC is greater than 1 (IC: 1.04; IC025: 0.40).
Other SSRIs reported with the investigated hearing disorders included sertraline, paroxetine, citalopram, escitalopram, fluvoxamine and zimeldine.""" ;
                  rdfs:label "Reports in Vgibase" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Selective_serotonin_reuptake_inhibitors
:Selective_serotonin_reuptake_inhibitors rdf:type owl:NamedIndividual ,
                                                  OpenPVSignal:DrugClass ;
                                         OpenPVSignal:has_mechanism :MechanismOfOtotoxicityBySSRI ;
                                         OpenPVSignal:has_ATC_code "N06AB" ;
                                         rdfs:label "Selective serotonin reuptake inhibitors" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#SummaryContent
:SummaryContent rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Summary ;
                mp:references :Ref.1 ;
                OpenPVSignal:has_content "VigiBase™ contains 122 individual case safety reports (ICSRs) of deafness, 324 ICSRs of tinnitus and 24 ICSRs of hyperacusis associated with the use of fluoxetine. These reactions are included in the US Product Information (PI)1 and the number of cases reporting a positive de- and rechallenge strengthens the likelihood that there is a causal relationship." ;
                rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#UK_SPC_for_fluoxetin
:UK_SPC_for_fluoxetin rdf:type owl:NamedIndividual ,
                               obo:OAE_0001197 ,
                               OpenPVSignal:Structured_Product_Labels_information ,
                               OpenPVSignal:Warning_Information ;
                      OpenPVSignal:refers_to_adverse_effect :tinnitus ;
                      OpenPVSignal:refers_to_drug :fluoxetine ;
                      mp:references :Ref.3 ;
                      OpenPVSignal:has_content "The UK Summary of Product Characteristics (SPC) lists tinnitus although frequency is not known.3" ;
                      rdfs:label "UK SPC for fluoxetin" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#US_PI_for_fluoxetin
:US_PI_for_fluoxetin rdf:type owl:NamedIndividual ,
                              obo:OAE_0001197 ,
                              OpenPVSignal:Structured_Product_Labels_information ,
                              OpenPVSignal:Warning_Information ;
                     OpenPVSignal:refers_to_adverse_effect :deafness ,
                                                           :hyperacusis ,
                                                           :tinnitus ;
                     OpenPVSignal:refers_to_drug :fluoxetine ;
                     mp:references :Ref.1 ;
                     OpenPVSignal:has_content "The US PI lists tinnitus as a frequent adverse event and deafness and hyperacusis as rare adverse events.1" ,
                                              "These reactions are included in the US Product Information (PI)1  and the number of cases reporting a positive de- and rechallenge strengthens the likelihood that there is a causal relationship." ;
                     rdfs:label "US PI for fluoxetin" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#anxiety
:anxiety rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Potential_Confounder ;
         OpenPVSignal:has_ICD_code "F419" ;
         OpenPVSignal:has_MedDRA_code 10002855 ;
         OpenPVSignal:has_MedDRA_prefered_term "Anxiety" ;
         rdfs:label "anxiety" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#bulimiaNervosa
:bulimiaNervosa rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Indication ;
                OpenPVSignal:has_MedDRA_code 10006550 ;
                OpenPVSignal:has_MedDRA_prefered_term "Bulimia nervosa" ;
                rdfs:label "bulimia nervosa" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#citalopram
:citalopram rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AB04" ;
            rdfs:label "citalopram" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#deafness
:deafness rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "H9190" ;
          OpenPVSignal:has_MedDRA_code 10011878 ;
          OpenPVSignal:has_MedDRA_prefered_term "Deafness" ;
          rdfs:label "deafness" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#depressiveIllness
:depressiveIllness rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Indication ,
                            OpenPVSignal:Potential_Confounder ;
                   OpenPVSignal:has_ICD_code "F33" ;
                   OpenPVSignal:has_MedDRA_code 10012378 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Depression" ;
                   rdfs:label "depressive illness" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#escitalopram
:escitalopram rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "N06AB10" ;
              rdfs:label "escitalopram" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#fluoxetine
:fluoxetine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:concerns_indication_for_use :bulimiaNervosa ,
                                                     :majorDepressiveIllness ,
                                                     :obsessive-compulsiveDisorder ;
            OpenPVSignal:hasClass :Selective_serotonin_reuptake_inhibitors ;
            OpenPVSignal:has_mechanism :MechanismOfFluoxetine ;
            OpenPVSignal:has_ATC_code "N06AB03" ,
                                      "N06CA03" ;
            rdfs:label "fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#fluvoxamine
:fluvoxamine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N06AB08" ;
             rdfs:label "fluvoxamine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#hyperacusis
:hyperacusis rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "H93.233" ;
             OpenPVSignal:has_MedDRA_code 10020559 ;
             OpenPVSignal:has_MedDRA_prefered_term "Hyperacusis" ;
             rdfs:label "hyperacusis" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#majorDepressiveIllness
:majorDepressiveIllness rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Indication ;
                        OpenPVSignal:has_ICD_code " F33" ;
                        OpenPVSignal:has_MedDRA_code 10057840 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Major depression" ;
                        rdfs:label "major depressive illness" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#obsessive-compulsiveDisorder
:obsessive-compulsiveDisorder rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Indication ;
                              OpenPVSignal:has_ICD_code "F429" ;
                              OpenPVSignal:has_MedDRA_code 10029898 ;
                              OpenPVSignal:has_MedDRA_prefered_term "Obsessive-compulsive disorder" ;
                              rdfs:label "obsessive-compulsive disorder" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#ototoxicity_studies_for_antidepressants
:ototoxicity_studies_for_antidepressants rdf:type owl:NamedIndividual ,
                                                  obo:OAE_0001125 ;
                                         OpenPVSignal:refers_to_adverse_effect <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Hearing_impairment_(SMQ)> ;
                                         OpenPVSignal:refers_to_class :Selective_serotonin_reuptake_inhibitors ;
                                         mp:references :Ref.11 ,
                                                       :Ref.12 ;
                                         OpenPVSignal:has_content """\"Some researchers tried to associate changes in several objective determinations of the hearing system (from otoscopy to the measurement of the central component of audition as brainstem responses) to the use of antidepressants in both depressed patients and non-depressed controls.
Results showed significantly smaller transient evoked emissions, higher SCAN-A (auditory processing test) composite scores, and smaller amplitude growth functions for auditory brainstem response peak V and auditory late response peak N(1)P(2) while on SSRI medication.11,12 Nevertheless, there is not a direct clinical correlation between the changes in those parameters and the clinical level of hearing, and the results must be taken with caution.\"""" ;
                                         rdfs:label "ototoxicity studies for antidepressants" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#paroxetine
:paroxetine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AB05" ;
            rdfs:label "paroxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :ConclusionContent ,
                                                   :IntroductionContent ,
                                                   :ReportsInVgibase ,
                                                   :SummaryContent ;
          OpenPVSignal:is_supported_by_statistical_entity :IC025ForDeafnessAndFluoxetine ,
                                                          :IC025ForHyperacusisAndFluoxetine ,
                                                          :IC025ForTinnitusAndFluoxetine ,
                                                          :ICForDeafnessAndFluoxetine ,
                                                          :ICForHyperacusisAndFluoxetine ,
                                                          :ICForTinnitusAndFluoxetine ,
                                                          :reportsInVigibaseForFluoxetineAndDeafness ,
                                                          :reportsInVigibaseForFluoxetineAndHyperacusis ,
                                                          :reportsInVigibaseForFluoxetineAndTinnitus ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAnddeafness)> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAndhyperacusis)> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAndtinnitus)> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAnddeafness)> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndhyperacusis)> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndtinnitus)> ;
          OpenPVSignal:refers_to_adverse_effect :deafness ,
                                                :hyperacusis ,
                                                :tinnitus ;
          OpenPVSignal:refers_to_drug :fluoxetine ;
          OpenPVSignal:refers_to_primary_suspect_drug :fluoxetine ;
          mp:supportedByData :Depression_associated_with_hearing_impairment ,
                             :Double-blind_clinical_trial ,
                             :Insufficient_evidence ,
                             :UK_SPC_for_fluoxetin ,
                             :US_PI_for_fluoxetin ,
                             :ototoxicity_studies_for_antidepressants ,
                             :reportsInVigibaseForFluoxetineAndDeafness ,
                             :reportsInVigibaseForFluoxetineAndHyperacusis ,
                             :reportsInVigibaseForFluoxetineAndTinnitus ,
                             <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAnddeafness)> ,
                             <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAndtinnitus)> ,
                             <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAnddeafness)> ,
                             <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndhyperacusis)> ,
                             <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndtinnitus)> ;
          OpenPVSignal:initially_identified_on "01/08/2020" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsInVigibaseForFluoxetineAndDeafness
:reportsInVigibaseForFluoxetineAndDeafness rdf:type owl:NamedIndividual ,
                                                    OpenPVSignal:Reports_group ;
                                           OpenPVSignal:refers_to_adverse_effect :deafness ;
                                           OpenPVSignal:refers_to_drug :fluoxetine ;
                                           OpenPVSignal:has_count 122 ;
                                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                           rdfs:label "reports in vigibase for fluoxetine and deafness" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsInVigibaseForFluoxetineAndHyperacusis
:reportsInVigibaseForFluoxetineAndHyperacusis rdf:type owl:NamedIndividual ,
                                                       OpenPVSignal:Reports_group ;
                                              OpenPVSignal:refers_to_adverse_effect :hyperacusis ;
                                              OpenPVSignal:refers_to_drug :fluoxetine ;
                                              OpenPVSignal:has_count 24 ;
                                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                              rdfs:label "reports in vigibase for fluoxetine and hyperacusis" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsInVigibaseForFluoxetineAndTinnitus
:reportsInVigibaseForFluoxetineAndTinnitus rdf:type owl:NamedIndividual ,
                                                    OpenPVSignal:Reports_group ;
                                           OpenPVSignal:refers_to_adverse_effect :tinnitus ;
                                           OpenPVSignal:refers_to_drug :fluoxetine ;
                                           OpenPVSignal:has_count 324 ;
                                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                           rdfs:label "reports in vigibase for fluoxetine and tinnitus" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reports_with_SSRI_and_hearing_disorders
:reports_with_SSRI_and_hearing_disorders rdf:type owl:NamedIndividual ,
                                                  OpenPVSignal:Reports_group ;
                                         OpenPVSignal:is_supported_by_statistical_entity :reports_with_SSRI_and_hearing_disorders ;
                                         OpenPVSignal:refers_to_adverse_effect <http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Hearing_impairment_(SMQ)> ;
                                         OpenPVSignal:refers_to_class :Selective_serotonin_reuptake_inhibitors ;
                                         OpenPVSignal:refers_to_drug :citalopram ,
                                                                     :escitalopram ,
                                                                     :fluvoxamine ,
                                                                     :paroxetine ,
                                                                     :sertraline ,
                                                                     :zimeldine ;
                                         rdfs:label "reports with SSRI and hearing disorders" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#sertraline
:sertraline rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AB06" ;
            rdfs:label "sertraline" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#tinnitus
:tinnitus rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "H931" ;
          OpenPVSignal:has_MedDRA_code 10043882 ;
          OpenPVSignal:has_MedDRA_prefered_term "Tinnitus" ;
          rdfs:label "tinnitus" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#usageOfFluoxetine
:usageOfFluoxetine rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Drug_Usage ;
                   OpenPVSignal:concerns_indication_for_use :bulimiaNervosa ,
                                                            :depressiveIllness ,
                                                            :obsessive-compulsiveDisorder ;
                   OpenPVSignal:refers_to_drug :fluoxetine ;
                   rdfs:label "usage of fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#zimeldine
:zimeldine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "N06AB02 " ;
           rdfs:label "zimeldine" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Hearing_impairment_(SMQ)
<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#Hearing_impairment_(SMQ)> rdf:type owl:NamedIndividual ,
                                                                                                    OpenPVSignal:Adverse_Effect ;
                                                                                           OpenPVSignal:has_MedDRA_code 20000171 ;
                                                                                           OpenPVSignal:has_MedDRA_prefered_term "Hearing impairment (SMQ)" ;
                                                                                           rdfs:label "Hearing impairment (SMQ)" ,
                                                                                                      "hearing impairment" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAnddeafness)
<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAnddeafness)> rdf:type owl:NamedIndividual ,
                                                                                                                                 OpenPVSignal:Reports_group ;
                                                                                                                        OpenPVSignal:is_subgroup_of :reportsInVigibaseForFluoxetineAndDeafness ;
                                                                                                                        OpenPVSignal:has_count 20 ;
                                                                                                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                        OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                                                                                                                        rdfs:label "reports with positive dechallenge (fluoxetine and deafness)" ,
                                                                                                                                   "reportsWithPositiveDechallenge(fluoxetineAnddeafness)" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAndhyperacusis)
<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAndhyperacusis)> rdf:type owl:NamedIndividual ,
                                                                                                                                    OpenPVSignal:Reports_group ;
                                                                                                                           OpenPVSignal:is_subgroup_of :reportsInVigibaseForFluoxetineAndHyperacusis ;
                                                                                                                           OpenPVSignal:has_count 6 ;
                                                                                                                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                           OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                                                                                                                           rdfs:label "reports with positive dechallenge (fluoxetine and hyperacusis)" ,
                                                                                                                                      "reportsWithPositiveDechallenge(fluoxetineAndhyperacusis)" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAndtinnitus)
<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveDechallenge(fluoxetineAndtinnitus)> rdf:type owl:NamedIndividual ,
                                                                                                                                 OpenPVSignal:Reports_group ;
                                                                                                                        OpenPVSignal:is_subgroup_of :reportsInVigibaseForFluoxetineAndTinnitus ;
                                                                                                                        OpenPVSignal:has_count 54 ;
                                                                                                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                        OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                                                                                                                        rdfs:label "reports with positive dechallenge (fluoxetine and tinnitus)" ,
                                                                                                                                   "reportsWithPositiveDechallenge(fluoxetineAndtinnitus)" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAnddeafness)
<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAnddeafness)> rdf:type owl:NamedIndividual ,
                                                                                                                                 OpenPVSignal:Reports_group ;
                                                                                                                        OpenPVSignal:is_subgroup_of :reportsInVigibaseForFluoxetineAndDeafness ;
                                                                                                                        OpenPVSignal:has_count 3 ;
                                                                                                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                        OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
                                                                                                                        rdfs:label "reports with positive rechallenge (fluoxetine and deafness)" ,
                                                                                                                                   "reportsWithPositiveRechallenge(fluoxetineAnddeafness)" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndhyperacusis)
<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndhyperacusis)> rdf:type owl:NamedIndividual ,
                                                                                                                                    OpenPVSignal:Reports_group ;
                                                                                                                           OpenPVSignal:is_subgroup_of :reportsInVigibaseForFluoxetineAndHyperacusis ;
                                                                                                                           OpenPVSignal:has_count 1 ;
                                                                                                                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                           OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
                                                                                                                           rdfs:label "reports with positive rechallenge (fluoxetine and hyperacusis)" ,
                                                                                                                                      "reportsWithPositiveRechallenge(fluoxetineAndhyperacusis)" .


###  http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndtinnitus)
<http://purl.org/OpenPVSignal/Signals/2013_3_fluoxetine_deafness#reportsWithPositiveRechallenge(fluoxetineAndtinnitus)> rdf:type owl:NamedIndividual ,
                                                                                                                                 OpenPVSignal:Reports_group ;
                                                                                                                        OpenPVSignal:is_subgroup_of :reportsInVigibaseForFluoxetineAndTinnitus ;
                                                                                                                        OpenPVSignal:has_count 7 ;
                                                                                                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                        OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
                                                                                                                        rdfs:label "reports with positive rechallenge (fluoxetine and tinnitus)" ,
                                                                                                                                   "reportsWithPositiveRechallenge(fluoxetineAndtinnitus)" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
